article thumbnail

Bispecific antibody startup Bambusa raises $90m to fund clinical trials

Pharmaceutical Technology

Two of Bambusas bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in 2025.

Antibody 162
article thumbnail

AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland

Pharmaceutical Technology

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Pharmaceutical Technology

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

article thumbnail

GSK, Vir build case for COVID-19 antibody drug with new study data

Bio Pharma Dive

Final clinical trial results confirmed treatment dramatically reduced the risk of hospitalization and death among adults with mild-to-moderate COVID-19.

Antibody 307
article thumbnail

Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy

Bio Pharma Dive

The company is paying China-based biotech LaNova Medicines $588 million for the type of dual-pronged antibody drug that recently bested Keytruda in a clinical trial.

article thumbnail

Lilly's antibody drug prevents COVID-19 in study, but hurdles to use remain

Bio Pharma Dive

Results from a clinical trial in nursing home residents and staff offered the first evidence Lilly's bamlanivimab could protect against, as well as treat, COVID-19

Nurses 293
article thumbnail

New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials

BioPharma Reporter

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

Antibody 143